In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Pasteur signs research deal with nanocarrier developer

This article was originally published in Scrip

Executive Summary

Sanofi Pasteurhas signed a research agreement with the privately held French biotechnology company In Cell Art to explore In Cell Art's nanocarrier technologies in Sanofi Pasteur's vaccine programmes. The nanocarriers form novel supramolecular groups that lead to efficient cellular and humoral responses for both prophylactic and therapeutic applications. In Cell Art hopes that if results from studies undertaken in the agreement are positive, the evaluation of its nanocarrier technologies will continue into Sanofi Pasteur's vaccine development. In Cell Art is also working on the commercialisation of ICAFectin441 and ICAFectin442, which are DNA and siRNA transfection reagents for primary and stem cells.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts